ERBB2 and subependymal giant cell astrocytoma: Furthermore, everolimus was approved for the treatment of advanced and unresectable cancers, including subependymal giant cell astrocytoma (SEGA), HER2-negative breast cancer, and progressive or metastatic pancreatic, gastrointestinal, and lung neuroendocrine tumors (NET) [62].